Trial Profile

A Global Multicenter Phase 1/2 Trial of EO4010, a Novel Microbial Derived Peptide Therapeutic Vaccine, in Combination With Nivolumab and/or Bevacizumab, for Treatment of Patients With Previously Treated Metastatic Colorectal Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 May 2025 Results presented data in the Enterome Media Release.
30 May 2025 According to Enterome Media Release, company will present data from this study at at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL, May 30-June 3.
11 Dec 2024 According to Enterome Media Release, initial clinical data from the ongoing Phase 1/2 AUDREY trial evaluating EO4010 in microsatellite stable metastatic colorectal cancer (CRC), will be presented at the ESMO Immuno-Oncology (IO) Congress, taking place in Geneva, Switzerland, December 11-13, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com